Nefopam Hydrochloride Ria Generics (Nefopam Hydrochloride)

The drug blocks the reuptake of norepinephrine, serotonin and dopamine and also inhibits voltage‑gated sodium channels. This combination reduces neuronal excitability and dampens pain signal transmission in the central nervous system, providing analgesia without opioid activity.

The appropriate dose of Nefopam Hydrochloride is determined by the prescribing clinician based on the patient’s condition, severity of pain, age, renal and hepatic function, and other individual factors. Dosage regimens are not standardized in this summary.

Safety data for Nefopam Hydrochloride in pregnancy and lactation are limited, and the product’s pregnancy category is not established. Clinicians should weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing women.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with opioid analgesics, Nefopam provides effective pain relief without the risk of respiratory depression, dependence or constipation. Unlike NSAIDs, it does not inhibit cyclo‑oxygenase enzymes, so it carries a lower risk of gastrointestinal bleeding but may have central nervous system side effects.

Store the oral product at ambient temperature, preferably below 25 °C, in its original container. Protect it from moisture, direct sunlight and excessive heat to maintain potency and stability throughout its shelf life.

Nefopam Hydrochloride is supplied as an oral formulation that is taken by mouth with water. The exact administration schedule, including timing relative to meals, should follow the prescribing clinician’s instructions.

Serious adverse events, though rare, include seizures, severe hypotension, cardiac arrhythmias, allergic reactions such as rash or swelling, and hepatic dysfunction. Patients should be monitored for these signs, especially if they have pre‑existing risk factors.

Nefopam should be avoided in individuals with uncontrolled hypertension, a history of seizures, severe renal or hepatic impairment, known hypersensitivity to the drug, or those currently taking monoamine oxidase inhibitors. Contra‑indications are determined by the prescribing healthcare professional.